Nanoform Finland Oyj · OMXHEX:NANOFH
Nanoform Finland Oyj — Nanoform — Q3 2026 Earnings Presentation
38 slides from Nanoform Finland Oyj's earnings presentation, Nov 19, 2026
Slide 1: Nanoform – Q3 2026
Nanoform – Q3 2026 Conference call and webcast for investors and analysts November 19th, 2026
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” believe,” “est
Slide 3: Intro & Key Business Highlights
01 Nanoform BreakerIntro & Slide Option 2 Key Business Highlights CEO Edward Hæggström Nanoform.com | @nanoform 3
Slide 4: Introduction to Nanoform
Introduction to Nanoform Proprietary Customers Nanoform Revenues to Midterm technology & partners technologies Nanoform business offering break the wall targets 2030 • Small Molecules • Global pharma • Small Molecules • Service fees 3 • Large Molecules • Mid-sized • Large Molecules • Development nan
Slide 5: State-of-the-art GMP certified facility in Helsinki for Small Molecules
State-of-the-art GMP certified facility in Helsinki for Small Molecules 3 Lead Small Molecule GMP manufacturing site for Small Molecules Product Kernels CESS® technology – cost, value, & environmental leader vs Nanoenzalutamide spray-dried ASDs Nanoapalutamide Nanoencorafenib 3 GMP manufacturing lin
Slide 6: Nanoform selects global CDMO partner for GMP manufacturing of Large Molecules
Nanoform selects global CDMO partner for GMP manufacturing of ultra-high-concentration Large Molecules Agreement signed 17.11.2026 Large Molecule GMP Implementing Nanoform’s proprietary Large Molecule technology at a readiness targeted European headquartered global CDMO H2 2027 Dedicated LM producti
Slide 7: Financials & Guidance
02 Nanoform Breaker Slide Option 2 Financials & Guidance CFO Albert Hæggström Nanoform.com | @nanoform 7
Slide 8: Nr of projects signed – proportion of GMP increasing
Nr of projects signed – proportion of GMP increasing Nr of projects signed Nr of projects signed - trailing 12 14 months 35 12 1 30 1 10 2 25 1 4 1 2 1 3 8 2 1 7 20 2 7 2 2 2 1 1 6 12 2 2 1 32 15 10 26 9 3 24 23 23 4 8 8 10 21 20 19 22 1 21 21 1 1 6 6 2 6 6 17 16 18 17 17 17 17 18 5 1 5 5 15 2 4 4 1
Slide 9: Strong growth in revenue, continued growth in total income. Gross margin almost 90%
Strong growth in revenue, continued growth in total income. Gross margin almost 90% 9M income (EURm) Gross margin % 3,50 100 % 93 % 91 % 90 % 86 % 88 % 3,00 79 % 80 % 2,50 72 % 70 % 66 % 2,00 60 % 1,50 50 % 40 % 1,00 30 % 0,50 20 % 0,00 10 % 9M20 9M21 9M22 9M23 9M24 9M25 9M26 0% Revenue Other operat
Slide 10: Operating expenses down by 35% in 9M26 => significant improvement in EBITDA
Operating expenses down by 35% in 9M26 => significant improvement in EBITDA Operating expenses (EURm) EBITDA (EURm) 0,0 0,0 -2,0 -4,0 -2,0 -6,0 -4,0 -8,0 -10,0 -6,0 -12,0 -14,0 -8,0 -16,0 -10,0 -18,0 -20,0 -12,0 9M20 9M21 9M22 9M23 9M24 9M25 9M26 Other operating expenses -14,0 Employee benefits expe
Slide 11: Nanoform near-term business targets 2026
Nanoform near-term business targets 2026 Cash burn below EUR 10m Near-term business targets First marketing authorisation application for a nanoformed medicine submitted 2026 Increased number of non-GMP and GMP projects signed in Four targets spanning cash, 2026 regulatory, projects, and commercial
Slide 12: Nanoform midterm business targets 2030
Nanoform midterm business targets 2030 3 Nanoformed medicines launched by 2030 Midterm business targets 2030 >50% Income* growth, CAGR 2026–2030 3 targets spanning launches, income growth, and profitability >30% EBIT margin by 2030 * Revenue + other operating income (milestones, fees, royalties, pro
Slide 13: Commercial
03 Nanoform Breaker Slide Option 2 Commercial CCO Christian Jones CDO Peter Hänninen Nanoform.com | @nanoform 13
Slide 14: Nanoform value proposition
Nanoform value proposition Large Molecules: from intravenous to Small Molecules: Smaller particles, better subcutaneous medicines • Nanoparticles as small as 50 nm • CESS® nanoparticles as small as 10 nm • Ultra-high concentration (>500 mg/ml) • Higher dissolution, solubility, bioavailability • Stab
Slide 15: Key commercial highlights
Key commercial highlights Agreement signed with global CDMO around Nanoform’s Ultra-High-Concentration Large Molecule technology, targeted readiness for GMP supply during 2H27 Project Nanoenzalutamide (prostate cancer) continues with the communicated multitrack strategy, submission of the first mark
Slide 16: Nanoform and Takeda α-1 antitrypsin dry powder for inhalation published
Nanoform and Takeda α-1 antitrypsin dry powder for inhalation using Nanoform’s novel particle Large Molecule technology published in Journal of Drug Delivery Science and Technology Why inhalation: <0.1% of an IV dose reaches the lung Respirable fraction of dose, nanoformed vs spray- (~98% stays in b
Slide 17: Nanoform recognised at PODD by PharmaCircle
Nanoform recognised at PODD by PharmaCircle: Centre stage among the globally leading technologies in subcutaneous Large Molecule delivery Ultra-high concentration: nanoparticle suspensions at >500 mg/mL Physical suspension stability: a key challenge for ultra-high-concentration Large Molecules Diffe
Slide 18: Positive demonstration >1g mAb delivered in <15 sec using autoinjector
Positive demonstration >1g mAb delivered in <15 sec using Midas/Gerresheimer autoinjector device Ultra-high-concentration mAb suspensions tested in Gerresheimer’s Gx Inbeneo autoinjector Concentrations of up to 560 mg/mL, tested at our Helsinki laboratories Encouraging initial results: rapid, patien
Slide 19: Nanoform Product Kernel overview
Nanoform Product Kernel overview* Nanoform Product Kernels Pre-Clinical (non-GMP) Clinical (GMP) At Market Dosage PoP* / Phase 1 / Pivotal - Delivery Nanoform Development Targeted Pre- First First Earliest Expected form Dosage Pilot final Originator Indication Nanoformed API route / ownership partne
Slide 20: Future of Large Molecule delivery & formulation
Future of Large Molecule delivery & formulation DELIVERY Subcutaneous delivery will become the dominant standard for new & marketed Large Molecules FORMULATION Suspension formulations enable high drug concentrations → lower injection volumes, making them a preferred choice TECHNOLOGY Particle proper
Slide 21: Named subcutaneous delivery licences, exclusive rights, platform access
Named subcutaneous delivery licences, exclusive rights, platform access - Dozens of large companies targeting 100s of receptors and only a handful of technology providers Enzyme (hyaluronidase) subcutaneous technologies Ultra-High concentration subcutaneous (UHCSUBQ) technologies Halozyme Alteogen H
Slide 22: Q&A - November 19th, 2026
Q&A - November 19th, 2026 Edward Hæggström Albert Hæggström Christian Jones Peter Hänninen CEO CFO CCO CDO & GC Nanoform.com | @nanoform 22
Slide 23: Appendix
04 Nanoform Breaker Slide Option 2 Appendix Nanoform.com | @nanoform 23
Slide 24: Nanoenzalutamide project continues with multitrack strategy
Nanoenzalutamide project continues with multitrack strategy EUROPEAN SUBMISSIONS Evaluating selected national submissions in European markets that may accept the current data package FORMULATION WORK Advancing further formulation work to also meet the remaining Cmax requirement NON-GENERIC PATHWAY A
Slide 25: Nanoform's CESS technology – Cost Leader vs Spray-dried ASDs
Nanoform’s CESS® technology – Cost Leader vs Spray-dried ASDs - September 22nd, 2026 COST LEADERSHIP 1 Lower cost of goods, high yields & simplified processing – kgs/hr and multi-tonne annual capacity in Helsinki VALUE LEADERSHIP 2 Comparable exposure to marketed ASDs with dramatically higher drug l
Slide 26: Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide
Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide – August 5th, 2026 PURPOSE Receive advice on the hybrid application pathway for a UK marketing authorisation application for nanoenzalutamide, using the existing clinical data package KEY OUTCOME A future UK applicat
Slide 27: Nanoform signs first Large Molecule technology exclusivity agreement
Nanoform signs first Large Molecule technology exclusivity agreement - May 12th, 2026 AGREEMENT Exclusivity agreement for ultra-high concentration Large Molecule subcutaneous delivery, with a U.S. Nasdaq listed biopharmaceutical company (Mcap USD 1Bn+) EXCLUSIVITY & UPFRONT PAYMENTS Non-refundable U
Slide 28: Nanotrastuzumab matches Herceptin HYLECTA in minipig study
Nanotrastuzumab matches Herceptin HYLECTA in minipig study - February 12th, 2026 NANOTRASTUZUMAB – SUBCUTANEOUS ca. 1 ml <30 s Subcutaneous injection time injection INTRAVENOUS – HERCEPTIN® SUBCUTANEOUS – LAUNCHED 2019 Loading dose over 90 min; later doses 600 mg with 10,000 units hyaluronidase week
Slide 29: Nanoform technologies supercharge performance of a wide variety of molecules
Nanoform technologies supercharges performance of a wide variety of molecules, products and indications Higher Dose Load for Improved Bioavailability Superior Alternative to Enhancement for Superior Oral drugs, mAbs, ASD Formulations Challenging Target Reformulations Peptides and Proteins Product Pr
Slide 30: Nanoform technology is proven with in-vitro, in-vivo, and clinical results
Nanoform technology is proven with in-vitro, in-vivo, and clinical study results and experience with 100 unique molecules ONCOLOGY LARGE MOLECULES HYDROGELS Demonstrated, in partnership with Shown high drug load 5 x more than Replaced ASD formulations with Takeda and other companies, high by nanomil
Slide 31: Small Molecules - Proprietary technology
Small Molecules - Proprietary technology Controlled Expansion of Supercritical Solutions – CESS® Green technology Supercritical CO₂ is guided into a pressure 1 vessel loaded with API Increasing the pressure and temperature in the 2 vessel dissolves the API in supercritical CO₂ The CO₂ and the API ar
Slide 32: Large Molecules - Proprietary technology
Large Molecules - Proprietary technology Nanoforming process for Large Molecules Green technology 1 API containing feed solution is pumped into the nebuliser 2 Feed solution is nebulised into a carrier gas Mist is transported into the drying chamber via a connection 3 pipe 4 Mist is dried using low-
Slide 33: Attractive revenue model with pharma and biotech customers
Attractive revenue model with pharma and biotech customers Proof of Concept / Proof of Phase I - III clinical trials Drugs on the market Process CERTIFICATION CERTIFICATION CERTIFICATION Non-GMP GMP GMP DESCRIPTION DESCRIPTION DESCRIPTION • Proof of concept study - • API for clinical trials are • Dr
Slide 34: Nanoform Product Kernels business model
Nanoform Product Kernels business model Nanoform internal Product Development partners Commercial partners Kernel work FOCUS PARTNER PARTNER Value proposition around a Originator or Supergeneric / High Originator or Supergeneric / High medicine candidate, called 'Product value medicine company value
Slide 35: Nanoform mid-term annual income potential by 2030
Nanoform mid-term annual income potential by 2030 Exclusivity fees, royalties & profit share > EUR 50m Commercial milestones, Small Molecules > EUR 25m Commercial GMP supply, Small Molecules > EUR 10m Development milestones, Large Molecules > EUR 10m Development milestones, Small Molecules > EUR 10m
Slide 36: Management team: Multi-disciplinary with international merits
Management team: Multi-disciplinary with international merits CEO & Co-founder; Ph.D. (Applied physics), MBA CFO and member of the Board; B.Sc. (Economics) Edward Hæggström Albert Hæggström • Professor at the University of Helsinki, Head of Electronics • 20 years of finance and investing experience
Slide 37: Board of directors: Top executives from leading industry positions
Board of directors: Top executives from leading industry positions Miguel Calado Jeanne Thoma Albert Hæggström Chairman of the Board Board Member CFO and Board Member • Previously CFO at international particle • 30+ years of experience in global • 20 years of finance and investing experience enginee
Slide 38: Contact details
CEO CFO & Board Member Dr. Edward Hæggström Albert Hæggström edward.haeggstrom@nanoform.com albert.haeggstrom@nanoform.com +358 29 370 0150 +358 29 370 0150 CCO Investor Relations Christian Jones Henri von Haartman christian.jones@nanoform.com hvh@nanoform.com +44 7804 474771 +46 76866 50 11 Nanofor